Boehringer moves forward with its glucagon/GLP-1 receptor dual agonist, survodutide.

"The German drugmaker is now preparing to launch a late-stage trial of its drug, which if approved, would compete with Eli Lilly’s Mounjaro and Novo Nordisk’s Wegovy. US pharma group Pfizer and biotech Regeneron are among the others hoping to enter the market."

#Metabolism #Pharma #DrugDevelopment #DrugDiscovery #Obesity

https://www.ft.com/content/d3f5e936-05af-4775-8247-cff1c007ba45